Search

Your search keyword '"Khan, Aziz"' showing total 1,400 results
Start Over Author "Khan, Aziz"
1,400 results on '"Khan, Aziz"'

4. Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in India

Author

Jadhav, Uday M., Ray, Saumitra, Unni, T. Govindan, Sawhney, J. P. S., Mehta, Ashwani, Guha, Shantanu, Karnik, Rajiv D., Desai, Bhupen N., Khan, Aziz, Patel, Keyur, Prajapati, Jayesh S., Shah, Hitesh J., Reddy, Rama Krishna, Kumar, Sanjeev, Dutta, Soumya Kanti, Chakraborty, Saujatya, Ahmed, Ashfaque, Prasad, Ravi Vishnu, Chaudhary, Gaurav, Kumar, Amit, Manjappa, M., Shetty, Sujal, Raja, Praveen, and Shanmugam, Vimalraj Bogana

Published
2024
Full Text
View/download PDF

5. Multiomic analysis of familial adenomatous polyposis reveals molecular pathways associated with early tumorigenesis

Author

Esplin, Edward D., Hanson, Casey, Wu, Si, Horning, Aaron M., Barapour, Nasim, Nevins, Stephanie A., Jiang, Lihua, Contrepois, Kévin, Lee, Hayan, Guha, Tuhin K., Hu, Zheng, Laquindanum, Rozelle, Mills, Meredith A., Chaib, Hassan, Chiu, Roxanne, Jian, Ruiqi, Chan, Joanne, Ellenberger, Mathew, Becker, Winston R., Bahmani, Bahareh, Khan, Aziz, Michael, Basil, Weimer, Annika K., Esplin, D. Glen, Shen, Jeanne, Lancaster, Samuel, Monte, Emma, Karathanos, Thomas V., Ladabaum, Uri, Longacre, Teri A., Kundaje, Anshul, Curtis, Christina, Greenleaf, William J., Ford, James M., and Snyder, Michael P.

Published
2024
Full Text
View/download PDF

11. Abstract 4142390: The LAI-OLS registry: Unveiling crucial insights into the challenges of managing LDL cholesterol in Indian patients with CAD

Author

Mahajan, Kunal, Gupta, Ashu, Batra, Aditya, Rana, Vivek, Kumar, Mukul, Gawalkar, Atit, Bhatia, Tanuj, Yadav, Rahul, Kumar, Dhananjay, Sharma, Jai Bharat, Theja, Pavan, Yadav, Ashwani, dev, munish, Himral, Surender, Thakur, Priyanka, Khandelwal, Sakshi, Pratap, Akshay, Khan, Aziz, Agarwala, Rajeev, and Puri, Raman

Published
2024
Full Text
View/download PDF

13. Some transforms, Riemann–Liouville fractional operators, and applications of newly extended M–L (p, s, k) function

Author

Ayub Umbreen, Mubeen Shahid, Abbas Amir, Khan Aziz, and Abdeljawad Thabet

Subjects
m–l (p, s, k)-function, whittaker transform, three-parameter gamma function, Physics, QC1-999
Abstract

There are several problems in physics, such as kinetic energy equation, wave equation, anomalous diffusion process, and viscoelasticity that are described well in the fractional differential equation form. Therefore, the solutions with elementary solution method cannot be solved and described deliberately with detailed physics of the problems, so these problems are solved with the help of special operators such as Mittag–Leffler (M–L) functions equipped with Riemann–Liouville (R–L) fractional operators. Hence, keeping in view the above-mentioned problems in physics in the current study, the generalized properties are derived M–L functions connected with R–L fractional operators that are investigated in the generalized form. These extended special operators will be used for the solutions of generalized kinetic energy equation. The M–L function is a fundamental special function with a wide range of applications in mathematics, physics, engineering, and various scientific disciplines. Ayub et al. gave the definition of newly extended M–L (p,s,k)\left(p,s,k) function. Also, they gave its convergence condition and found several results relevant to that. The purpose of this study is to investigate newly extended M–L function and study its elementary properties and integral transforms such as Whittaker transform and fractional Fourier transform. The R–L fractional operator is a fundamental concept in fractional calculus, a branch of mathematics that generalizes differentiation and integration to non-integer orders. In this study, we discuss the relation of M–L (p,s,k)\left(p,s,k)-function and R–L fractional operators. In some cases, fractional calculus is used to describe kinetic energy equations, particularly in systems where fractional derivatives are more appropriate than classical integer-order derivatives. The M–L function can appear as a solution or as a part of the solution to these fractional kinetic energy equations. Also, we gave the generalization of kinetic energy equation and its solution in terms of newly extended M–L function.

Published
2024
Full Text
View/download PDF

19. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease

Author

Toth, Peter P, Schwartz, Gregory G, Nicholls, Stephen J, Khan, Aziz, Szarek, Michael, Ginsberg, Henry N, Johansson, Jan O, Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina, Lebioda, Ken, Wong, Norman CW, Sweeney, Michael, Ray, Kausik K, and Investigators, BETonMACE

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cardiovascular, Chronic Liver Disease and Cirrhosis, Prevention, Liver Disease, Heart Disease, Clinical Trials and Supportive Activities, Clinical Research, Heart Disease - Coronary Heart Disease, Digestive Diseases, Atherosclerosis, Diabetes, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Apabetalone, Cardiovascular events, Fibrosis, Nonalcoholic fatty liver disease, BETonMACE Investigators, ACS, Acute coronary syndrome, ALP, Alkaline Phosphatase, ALT, Alanine aminotransferase, APR, Acute phase reactant, AST, Aspartate aminotransferase, ApoAI, Aproprotein-AI, BD, Bromodoamin, BET, Bromodomain and extraterminal proteinfamily, BMI, Body mass index, CV, Cardiovascular, CVD, Cardiovascular Disease, FS, Fibrosis score, HDL-C, High density lipoprotein cholesterol, HHF, Hospitalization for heart Failure, HR, Hazard ratio, MACE, Major acute coronary event, NAFLD, Nonalcoholic fatty liver disease, T2DM, Type 2 diabetes mellitus, Cardiovascular medicine and haematology
Abstract

BackgroundNonalcoholic fatty liver disease (NAFLD) is common among patients with type 2 diabetes mellitus (T2DM) and is associated with increased risk for coronary atherosclerosis and acute cardiovascular (CV) events. We employed the validated, non-invasive Angulo NAFLD fibrosis score (FS) in an intervention study in patients with T2DM and recent acute coronary syndrome (ACS) to determine the association of FS with CV risk and treatment response to apabetalone. Apabetalone is a novel selective inhibitor of the second bromodomain of bromodomain and extra-terminal (BET) proteins, epigenetic regulators of gene expression.MethodsThe Phase 3 BETonMACE trial compared apabetalone with placebo in 2,425 patients with T2DM and recent ACS. In this post hoc analysis, we evaluated the impact of apabetalone therapy on CV risk, defined as a composite of major adverse cardiovascular events (MACE: CV death, non-fatal myocardial infarction [MI], or stroke) and hospitalization for heart failure (HHF) in two patient categories of FS that reflect the likelihood of underlying NAFLD. Patients were initially classified into three mutually exclusive categories according to a baseline Angulo FS 0.675 (F3-F4), where F0 through F4 connote fibrosis severity none, mild, moderate, severe, and cirrhosis, respectively. The composite of ischemic MACE and HHF in the placebo group was higher in indeterminant and F3-F4 categories compared to the F0-F2 category (17.2% vs 15.0% vs 9.7%). Therefore, for the present analysis, the former two categories were combined into an elevated NAFLD CVD risk group (FS+) that was compared with the F0-F2 group (lower NAFLD risk, FS0-2).ResultsIn 73.7% of patients, FS was elevated and consistent with a moderate-to-high likelihood of advanced liver fibrosis (FS+); 26.3% of patients had a lower FS (FS0-2). In the placebo group, FS+ patients had a higher incidence of ischemic MACE and HHF (15.4%) than FS0-2 patients (9.7%). In FS+ patients, addition of apabetalone to standard of care treatment lowered the rate of ischemic MACE compared with placebo (HR = 0.79; 95% CI 0.60-1.05; p=0.10), HHF (HR = 0.53; 95% CI 0.33-0.86; p=0.01), and the composite of ischemic MACE and HHF (HR = 0.76; 95% CI 0.59-0.98; p=0.03). In contrast, there was no apparent benefit of apabetalone in FS0-2 patients (HR 1.24; 95% CI 0.75-2.07; p=0.40; HR 1.12; 95% CI 0.30-4.14; p=0.87; and HR 1.13; 95% CI 0.69-1.86; p=0.62, respectively). Over a median duration of 26.5 months, FS increased from baseline in both treatment groups, but the increase was smaller in patients assigned to apabetalone than to placebo (p=0.04).ConclusionsAmongst patients with T2DM, recent ACS, and a moderate-to-high likelihood of advanced liver fibrosis, apabetalone was associated with a significantly lower rate of ischemic MACE and HHF and attenuated the increase in hepatic FS over time.

Published
2022

28. Prevalence of atrial fibrillation on a 24-hour Holter in adult Indians

Author

Rao, M Srinivasa, Mullasari, Ajit, Hiremath, Jagdish S., Sengottuvelu, G., Jaiswal, Aparna, Jhala, Darshan, Makkar, Jitendra Singh, Kalmath, B.C., Benjamin, Bino, Dharmadhikari, Annirudha, Tanna, Mihir, Khan, Aziz, Jain, Siddhant, Sambasivam, K.A., Purnanand, A., Raju, N S Rama, Sarkar, Goutam, Prajapati, Hiren, and verberk, Willem J.

Published
2024
Full Text
View/download PDF

29. Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: Consensus statement IV

Author

Puri, Raman, Bansal, Manish, Mehta, Vimal, Duell, P. Barton, Wong, Nathan D., Iyengar, S.S., Kalra, Dinesh, Nair, Devaki R., Nanda, Navin C., Narula, Jagat, Deedwania, P., Yusuf, Jamal, Dalal, Jamshed J., Shetty, Sadanand, Vijan, Vinod M., Agarwala, Rajeev, Kumar, Soumitra, Vijay, Kris, Khan, Aziz, Wander, Gurpreet Singh, Manoria, P.C., Wangnoo, S.K., Mohan, Viswanathan, Joshi, Shashank R., Singh, Balbir, Kerkar, Prafulla, Rajput, Rajesh, Prabhakar, D., Zargar, Abdul Hamid, Saboo, Banshi, Kasliwal, Ravi R., Ray, Saumitra, Bansal, Sandeep, Rabbani, M.U., Chhabra, Shibba Takkar, Chandra, Sarat, Bardoloi, Neil, Kavalipati, Narasaraju, Sathyamurthy, Immaneni, Mahajan, Kunal, Pradhan, Akshya, Khanna, N.N., Khadgawat, Rajesh, Gupta, Preeti, Chag, Milan C., Gupta, Ashu, Murugnathan, A., Narasingan, S.N., Upadhyaya, Sundeep, Mittal, Vinod, Melinkeri, Rashida Patanwala, Yadav, Madhur, Mubarak, M. Raseed, Pareek, K.K., Dabla, Pradeep Kumar, Nanda, Rashmi, and Mohan, J.C.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results